The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
E Karran, B De Strooper - Nature reviews Drug discovery, 2022 - nature.com
Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …
The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
Trial of solanezumab in preclinical Alzheimer's disease
RA Sperling, MC Donohue, R Raman… - … England Journal of …, 2023 - Mass Medical Soc
Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …
Biomarkers for neurodegenerative diseases
O Hansson - Nature medicine, 2021 - nature.com
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …
Emerging diagnostics and therapeutics for Alzheimer disease
WK Self, DM Holtzman - Nature medicine, 2023 - nature.com
Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …
strategies that slow or prevent its clinical progression have largely remained elusive, until …
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
Synergy between amyloid-β and tau in Alzheimer's disease
Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …
Global estimates on the number of persons across the Alzheimer's disease continuum
A Gustavsson, N Norton, T Fast, L Frölich… - Alzheimer's & …, 2023 - Wiley Online Library
Introduction Global estimates on numbers of persons in early stages of Alzheimer's disease
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …
(AD), including prodromal and preclinical, are lacking, yet are needed to inform policy …
[PDF][PDF] Spatial transcriptomics and in situ sequencing to study Alzheimer's disease
Although complex inflammatory-like alterations are observed around the amyloid plaques of
Alzheimer's disease (AD), little is known about the molecular changes and cellular …
Alzheimer's disease (AD), little is known about the molecular changes and cellular …